Ultomiris Granted Priority Review in the U.S. as Treatment for Adults With Immunoglobulin A Nephropathy
June 16, 2026
June 16, 2026
WILMINGTON, Delaware, June 16 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
Based on I CAN Phase III trial results from prespecified interim analysis in which ULTOMIRIS demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks
If approved, ULTOMIRIS would be the first C5 com . . .
* * *
ULTOMIRIS(R) (ravulizumab-cwvz) granted Priority Review in the US as treatment for adults with immunoglobulin A nephropathy
Based on I CAN Phase III trial results from prespecified interim analysis in which ULTOMIRIS demonstrated 43.4% reduction in proteinuria vs placebo at 34 weeks
If approved, ULTOMIRIS would be the first C5 com . . .